Vietnam's VNVC Vaccine Plant in Tay Ninh to Begin Production in Late 2027
The VNVC Vaccine and Biological Products plant, located in Tay Ninh province, Vietnam, is scheduled to commence operations by the end of 2027. The facility represents a significant investment, with its total value exceeding 2.5 trillion Vietnamese Dong. Production of the first vaccines is anticipated to begin in 2028. This initial phase of production will be undertaken in collaboration with the global pharmaceutical company Sanofi. The plant's establishment marks a key development in Vietnam's domestic vaccine manufacturing capabilities.
The establishment of the VNVC vaccine plant signifies Vietnam's strategic move to bolster domestic pharmaceutical production, reducing reliance on international suppliers. This initiative aligns with global trends toward supply chain resilience in critical sectors like healthcare. The collaboration with Sanofi suggests a focus on leveraging established expertise and technology transfer to meet international quality standards. Over the next decade, such investments will be crucial for national health security and potentially for regional vaccine supply, especially in the context of evolving public health challenges and the increasing importance of biotechnology.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.